AusCann buys a research and development facility in Perth

Company News

by Rachael Jones

Medical cannabis company AusCann Group Holdings (ASX:AC8) has bought a research and development facility in Perth in WA.

The facility will focus on AusCann’s cannabinoid pharmaceutical product pipeline, supporting development of both innovative formulations and dose forms.

AusCann Executive Director and interim CEO Dr Paul MacLeman says it allows the creation of a fully integrated, state of the art facility for medicinal cannabis.

Shares in AusCann Group Holdings (ASX:AC8) are trading 1.57 per cent higher at $0.65.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.